The Weight of Expectations: Novo Nordisk's Stumble in the Battle for Obesity Solutions Novo Nordisk's stock has stumbled, leaving investors wondering if the company's flagship obesity fighting pill, Wegovy, can maintain its momentum against Eli Lilly.
Despite still holding a slight edge over its competitor, the margin is narrowing. A Battle of Giants The competition between Novo Nordisk and Eli Lilly has been building for years.
Once a laggard in the obesity treatment market, Novo Nordisk had gained ground with its injectable medications.